Intellipharmaceutics International Inc. (IPCI)

[fabius]

Samsa, Amigo,

my idea is that we had a change in the market consideration about IPCI's management over the last 3-4 months and I believe this started to materialize after the keppra approval.

The management made 3 mistakes (JMO) and they are now paying the price:

1 - keppra approval pushed share price above 3$; confidence in IPCI was high at that time; then not having a plan for an approved drug (even if the drug is marginal in terms of potential revenue) was a bad sign

2 - (something Sprot Always mention): IPCI didn't inform the market about the deadline of the Agreement with TEVA regarding one of the ANDA. It became clear only during quarterly report that the deal was overdue. Bad communication is never good

3 - the worst (for me): very bad timing for the new share issuance

It's therefore clear to me that the management has now the responsability to regain market confidence, which I think (as someone else here) will be IF the Rexista partnership looks strong financially and strategically.

Having said that, the ANDAs strategy was initially good; just consider that they are waiting since 5yrs (5 years!!) for approvals; its beyond reasonable business risk assessment for any co.
FDA stating it will clear the backlog by year-end looks ridicolous to me...but would be fun to see what happen if by march 2017 we have all the pending ANDAs approved.

Last point: Rexista is the elephant in the room, but from now until december we should get positive developments on other products. Many here are considering IPCI like a single product biotech...which is NOT.